Saratov JOURNAL of Medical and Scientific Research

Effectiveness of neure-protective therapy in patients with glaucoma

Year: 2018, volume 14 Issue: №4 Pages: 828-831
Heading: Ophtalmology Article type: Case report
Authors: Aprelev А.Е., Barbos Yu.A., Mukhanko I.Zh., Cherednichenko N.L., Abdulgazizova Z.F., Kataganova A.A., Bernovskaya A.A.
Organization: Mineralovodsky district hospital, Orenburg Regional Clinical Hospital, Orenburg State Medical University, Regional Clinical Diagnostic Center in Stavropol City, Stavropol Regional Clinical Hospital, Stavropol State Medical University

The results of clinical evaluation of three patients who were included in the multicenter study of the
effectiveness of neuroprotective treatment and its impact on the quality of life of patients with POAG are
presented in the article. Dynamics of visual acuity, intraocular pressure, total visual fields, photostress
test, contrast sensitivity and quality of life (according to the NEIVFQ-25 questionnaire) in patients
treated with neuroprotective study drug with 10 intramuscular injections administered 5mg once a day
are presented. Data on the improvement of visual functions and quality of life in patients with Stage I, II
and III of POAG who had undergone treatment with the study drug are demonstrated.

Keywords: quality of life

1 Novik AA, lonov Tl. Guide to the study of quality of life in medicine / Shevchenko YuL, ed. Moscow: OLMA Media Group 2007; 320 p.
2 Doozandeh A, Yazdani S. Neuroprotection in Glaucoma. J Ophthalmic Vis Res 2016; 11 (2): 209-20
3 Egorov EA, Egorova ТЕ, Shramko YuG. Effect of Retinalamin usage in patients with compensated primary open- angle glaucoma. Russian Journal of Clinical Ophthalmology 2014; 4 (4): 188-93
4 Gabdrakhmanova AF, Aznabaeva LF, Abizgildina GSh, et al. Molecular mechanisms of neuroretinoprotection in primary open-angle glaucoma. Vestnik Oftalmologii 2018; 134 (5): 54-60
5 Aprelev АЕ, Barbos YuA, Mukhanko IZh, et al. Dynamics of functional indicators of the visual organ and quality of life of patients with glaucoma against the background of neuroprotective treatment. Practical medicine 2018; 16 (4): 84-6.

2018_4-2_828-831.pdf261.13 KB

No votes yet